Chronic illness treatment in danger from Trump
My father has been battling cardiomyopathy for what seems like forever. He has undergone a multitude of treatments [and] been the recipient of experimental therapies and drugs, all [to] little to no avail. There is no cure for this disease, so we're stuck in an endless trial-and-error process, relishing even the smallest of successes.
However, his options could be completely extinguished if one of President Trump's latest executive orders, the Most Favored Nations order, actually takes hold. Included in this order is the International Pricing Index (IPI), a policy that threatens the very research being done to cure conditions like cardiomyopathy and also the important work being done to combat COVID-19.
This policy is short-sighted and fails to consider both its short and long-term implications. In the near future, its impact could deter further investment in advancing treatments and finding a vaccine for the coronavirus; and in the long-term, the IPI could mean depriving my father, and hundreds of thousands of other Oregonians, of the healthy futures they have been fighting for.
The funding and research directly related to investing shouldn't be curbed; it's only invested in producing the best possible product, one that is both safe and effective for a multitude of patients. Companies choose to invest in the American market, of all markets, because outcomes are better and odds of success are higher here. An IPI, however, could destroy those incentives and the American market alongside it.
Oregon's representatives must make known their opposition to this policy, which directly threatens the development of treatments and therapies for COVID-19, as well as those for chronic illnesses.
Jordan Miller is a resident of Oregon City.
You count on us to stay informed and we depend on you to fund our efforts. Quality local journalism takes time and money. Please support us to protect the future of community journalism.